It was found that there was insignificant value between JAK2 V617F burden allele median at the level of genotypes TC, CC and TC + CC compared to reference TT genotype (48.2 %, 50.1 %, 49.15 % and 49.1 % respectively in PV patients) (P > 0.05), (18.9 %, 19.5 %, 19.2 % and 20.1% respectively in ET patients) (P > 0.05) and (35.0%, 33.7%, 34.35% and 34.1% respectively in PMF patients) (P > 0.05). Here, JAK2 is linked to essential thrombocythemia.